Catalyst Capital Advisors LLC Seagen Inc. Transaction History

Catalyst Capital Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$191.51 - $216.16 $6,894 - $7,781	36 Added 34.95%	139 $29,000
Q2 2023 Aug 08, 2023	SELL	$187.64 - $206.25 $1,125 - $1,237	-6 Reduced 5.5%	103 $19,000
Q1 2023 May 12, 2023	SELL	$127.59 - $203.08 $4,593 - $7,310	-36 Reduced 24.83%	109 $22,000
Q4 2022 Feb 07, 2023	SELL	$117.37 - $139.17 $234 - $278	-2 Reduced 1.36%	145 $19,000
Q2 2022 Aug 09, 2022	BUY	$108.81 - $179.33 $2,285 - $3,765	21 Added 16.67%	147 $26,000

Q1 2022 May 10, 2022	BUY	$119.61 - $157.85 $2,990 - $3,946	25 Added 24.75%	126 $18,000
Q4 2021 Feb 10, 2022	SELL	$142.57 - $190.86 $1,140 - $1,526	-8 Reduced 7.34%	101 $16,000
Q3 2021 Nov 09, 2021	SELL	$142.45 - $169.82 $284 - $339	-2 Reduced 1.8%	109 $19,000
Q2 2021 Aug 06, 2021	BUY	$135.08 - $161.1 $540 - $644	4 Added 3.74%	111 $18,000
Q1 2021 May 10, 2021	SELL	$137.51 - $190.8 $2,750 - $3,816	-20 Reduced 15.75%	107 $15,000
Q4 2020 Feb 05, 2021	BUY	$164.63 - $211.93 $20,908 - $26,915	127 New	127 $22,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Catalyst Capital Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Catalyst Capital Advisors LLC with notifications on news.